RAS signalling in the colorectum in health and disease

REFERENCES

• Abubaker J, Bavi P, Al-Haqawi W, Sultana M, Al-Harbi S, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Uddin S, Al-Kuraya KS (2009). Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. J Pathol. 219: 435–445.
   PubMed Web of Science ®Google Scholar
• Akao Y, Nakagawa Y, Naoe T (2006). let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharmacuet Bull. 29: 903–906.
   PubMed Web of Science ®Google Scholar
• Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD (2008). Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 26: 1626–1634.
   PubMed Web of Science ®Google Scholar
• Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R, Jullian E, Laurent-Puig P, Olschwang S, Muller O, Hoffmann I, Rabes HM, Zietz C, Troungos C, Valavanis C, Yuen ST, Ho JW, Croke CT, O'Donoghue DP, Giaretti W, Rapallo A, Russo A, Bazan V, Tanaka M, Omura K, Azuma T, Ohkusa T, Fujimori T, Ono Y, Pauly M, Faber C, Glaesener R, de Goeij AF, Arends JW, Andersen SN, Lovig T, Breivik J, Gaudernack G, Clausen OP, De Angelis PD, Meling GI, Rognum TO, Smith R, Goh HS, Font A, Rosell R, Sun XF, Zhang H, Benhattar J, Losi L, Lee JQ, Wang ST, Clarke PA, Bell S, Quirke P, Bubb VJ, Piris J, Cruickshank NR, Morton D, Fox JC, Al-Mulla F, Lees N, Hall CN, Snary D, Wilkinson K, Dillon D, Costa J, Pricolo VE, Finkelstein SD, Thebo JS, Senagore AJ, Halter SA, Wadler S, Malik S, Krtolica K, Urosevic N (2001). Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study. Br J Canc. 85: 692–696.
   PubMed Web of Science ®Google Scholar
• Arena S, Isella C, Martini M, de Marco A, Medico E, Bardelli A (2007). Knock-in of oncogenic Kras does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers. Canc Res. 67: 8468–8476.
   PubMed Web of Science ®Google Scholar
• Barbacid M (1987). ras genes. Annu Rev Biochem. 56: 779–827.
   PubMed Web of Science ®Google Scholar
• Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, Frohling S, Chan EM, Sos ML, Michel K, Mermel C, Silver SJ, Weir BA, Reiling JH, Sheng Q, Gupta PB, Wadlow RC, Le H, Hoersch S, Wittner BS, Ramaswamy S, Livingston DM, Sabatini DM, Meyerson M, Thomas RK, Lander ES, Mesirov JP, Root DE, Gilliland DG, Jacks T, Hahn WC (2009). Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 462: 108–112.
   PubMed Web of Science ®Google Scholar
• Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, Olson JA, Jr., Marks JR, Dressman HK, West M, Nevins JR (2006). Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 439: 353–357.
   PubMed Web of Science ®Google Scholar
• Bivona TG, Quatela SE, Bodemann BO, Ahearn IM, Soskis MJ, Mor A, Miura J, Wiener HH, Wright L, Saba SG, Yim D, Fein A, Perez de Castro I, Li C, Thompson CB, Cox AD, Philips MR (2006). PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis. Mol Cell. 21: 481–493.
   PubMed Web of Science ®Google Scholar
• Brosens RP, Haan JC, Carvalho B, Rustenburg F, Grabsch H, Quirke P, Engel AF, Cuesta MA, Maughan N, Flens M, Meijer GA, Ylstra B (2010). Candidate driver genes in focal chromosomal aberrations of stage II colon cancer. J Pathol. 221: 411–424.
   PubMed Web of Science ®Google Scholar
• Castagnola P, Giaretti W (2005). Mutant KRAS, chromosomal instability and prognosis in colorectal cancer. Biochim Biophys Acta. 1756: 115–125.
   PubMed Web of Science ®Google Scholar
• Cobb MH, Goldsmith EJ (1995). How MAP kinases are regulated. J Biol Chem. 270: 14843–14846.
   PubMed Web of Science ®Google Scholar
• Cogoi S, Paramasivam M, Membrino A, Yokoyama KK, Xodo LE (2010). The KRAS promoter responds to Myc-associated zinc finger and poly(ADP-ribose) polymerase 1 proteins, which recognize a critical quadruplex-forming GA-element. J Biol Chem. 285: 22003–22016.
   Google Scholar
• De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S (2010). Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 11: 753–762.
   PubMed Web of Science ®Google Scholar
• DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, Scrimieri F, Winter JM, Hruban RH, Iacobuzio-Donahue C, Kern SE, Blair IA, Tuveson DA (2011). Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 475: 106–109.
   PubMed Web of Science ®Google Scholar
• Downward J (2003). Targeting RAS signalling pathways in cancer therapy. Nat Rev Canc. 3: 11–22.
   PubMed Web of Science ®Google Scholar
• Fearon ER, Vogelstein B (1990). A genetic model for colorectal tumorigenesis. Cell. 61: 759–767.
   PubMed Web of Science ®Google Scholar
• Fest T, Mougey V, Dalstein V, Hagerty M, Milette D, Silva S, Mai S (2002). c-MYC overexpression in Ba/F3 cells simultaneously elicits genomic instability and apoptosis. Oncogene. 21: 2981–2990.
   PubMed Web of Science ®Google Scholar
• Fukasawa K, Vande Woude GF (1997). Synergy between the Mos/mitogen-activated protein kinase pathway and loss of p53 function in transformation and chromosome instability. Mol Cell Biol. 17: 506–518.
   PubMed Web of Science ®Google Scholar
• Gao JS, Zhang Y, Tang X, Tucker LD, Tarwater PM, Quesenberry PJ, Rigoutsos I, Ramratnam B (2011). The Evi1, microRNA-143, K-Ras axis in colon cancer. FEBS Lett. 585: 693–699.
   PubMed Web of Science ®Google Scholar
• Goldfarb M, Shimizu K, Perucho M, Wigler M (1982). Isolation and preliminary characterization of a human transforming gene from T24 bladder carcinoma cells. Nature. 296: 404–409.
   PubMed Web of Science ®Google Scholar
• Guerra C, Mijimolle N, Dhawahir A, Dubus P, Barradas M, Serrano M, Campuzano V, Barbacid M (2003). Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Canc Cell. 4: 111–120.
   PubMed Web of Science ®Google Scholar
• Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN, Niwa-Kawakita M, Sweet-Cordero A, Sebolt-Leopold J, Shannon KM, Settleman J, Giovannini M, Jacks T (2008). Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet. 40: 600–608.
   PubMed Web of Science ®Google Scholar
• Hall A, Marshall CJ, Spurr NK, Weiss RA (1983). Identification of transforming gene in two human sarcoma cell lines as a new member of the ras gene family located on chromosome 1. Nature. 303: 396–400.
   PubMed Web of Science ®Google Scholar
• Harvey JJ (1964). An unidentified virus which causes the rapid production of tumours in mice. Nature. 204: 1104–1105.
   PubMed Web of Science ®Google Scholar
• Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS (2002). A central role for JNK in obesity and insulin resistance. Nature. 420: 333–336.
   PubMed Web of Science ®Google Scholar
• Janssen KP, el-Marjou F, Pinto D, Sastre X, Rouillard D, Fouquet C, Soussi T, Louvard D, Robine S (2002). Targeted expression of oncogenic K-ras in intestinal epithelium causes spontaneous tumorigenesis in mice. Gastroenterology. 123: 492–504.
   PubMed Web of Science ®Google Scholar
• Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ (2005). RAS is regulated by the let-7 microRNA family. Cell. 120: 635–647.
   PubMed Web of Science ®Google Scholar
• Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR (2008). K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 359: 1757–1765.
   PubMed Web of Science ®Google Scholar
• Katz ME, McCormick F (1997). Signal transduction from multiple Ras effectors. Curr Opin Genet Dev. 7: 75–79.
   PubMed Web of Science ®Google Scholar
• Kinzler KW, Vogelstein B (1996). Lessons from hereditary colorectal cancer. Cell. 87: 159–170.
   PubMed Web of Science ®Google Scholar
• Krens LL, Baas JM, Gelderblom H, Guchelaar HJ (2010). Therapeutic modulation of k-ras signaling in colorectal cancer. Drug Discov Today. 15: 502–516.
   PubMed Web of Science ®Google Scholar
• Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA, Jacks T (2008). Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci U S A. 105: 3903–3908.
   PubMed Web of Science ®Google Scholar
• Lamb J, Ramaswamy S, Ford HL, Contreras B, Martinez RV, Kittrell FS, Zahnow CA, Patterson N, Golub TR, Ewen ME (2003). A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell. 114: 323–334.
   PubMed Web of Science ®Google Scholar
• Lee AC, Fenster BE, Ito H, Takeda K, Bae NS, Hirai T, Yu ZX, Ferrans VJ, Howard BH, Finkel T (1999). Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species. J Biol Chem. 274: 7936–7940.
   PubMed Web of Science ®Google Scholar
• Li YC, Chen CR, Chang EC (2000). Fission yeast Ras1 effector Scd1 interacts with the spindle and affects its proper formation. Genetics. 156: 995–1004.
   PubMed Web of Science ®Google Scholar
• Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, Papadimitriou CA, Murray S (2008). Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 9: 962–972.
   PubMed Web of Science ®Google Scholar
• Little AS, Balmanno K, Sale MJ, Newman S, Dry JR, Hampson M, Edwards PA, Smith PD, Cook SJ (2011). Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci Signal. 4: ra17.
   PubMed Web of Science ®Google Scholar
• Luo F, Brooks DG, Ye H, Hamoudi R, Poulogiannis G, Patek CE, Winton DJ, Arends MJ (2007). Conditional expression of mutated K-ras accelerates intestinal tumorigenesis in Msh2-deficient mice. Oncogene. 26: 4415–4427.
   PubMed Web of Science ®Google Scholar
• Luo F, Brooks DG, Ye H, Hamoudi R, Poulogiannis G, Patek CE, Winton DJ, Arends MJ (2009). Mutated K-rasAsp12 promotes tumourigenesis in ApcMin mice more in the large than the small intestines, with synergistic effects between K-ras and Wnt pathways. Int J Exp Pathol. 90: 558–574.
   PubMed Web of Science ®Google Scholar
• Luo F, Poulogiannis G, Ye H, Hamoudi R, Arends MJ (2011a). Synergism between K-rasVal12 and mutant Apc accelerates murine large intestinal tumourigenesis. Oncol Rep. 26: 125–133.
   PubMed Web of Science ®Google Scholar
• Luo F, Poulogiannis G, Ye H, Hamoudi R, Zhang W, Dong G, Arends MJ (2011b). Mutant K-ras promotes carcinogen-induced murine colorectal tumourigenesis, but does not alter tumour chromosome stability. J Pathol. 223: 390–399.
   PubMed Web of Science ®Google Scholar
• Luo F, Ye H, Hamoudi R, Dong G, Zhang W, Patek CE, Poulogiannis G, Arends MJ (2010). K-ras exon 4A has a tumour suppressor effect on carcinogen-induced murine colonic adenoma formation. J Pathol. 220: 542–550.
   PubMed Web of Science ®Google Scholar
• Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, Wong KK, Elledge SJ (2009). A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell. 137: 835–848.
   PubMed Web of Science ®Google Scholar
• Maher J, Baker DA, Manning M, Dibb NJ, Roberts IA (1995). Evidence for cell-specific differences in transformation by N-, H- and K-ras. Oncogene. 11: 1639–1647.
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M (2003). RAS oncogenes: the first 30 years. Nat Rev Canc. 3: 459–465.
   PubMed Web of Science ®Google Scholar
• McCormick F (1999). Signalling networks that cause cancer. Trends Cell Biol. 9: M53–M56.
   PubMed Web of Science ®Google Scholar
• Mita H, Toyota M, Aoki F, Akashi H, Maruyama R, Sasaki Y, Suzuki H, Idogawa M, Kashima L, Yanagihara K, Fujita M, Hosokawa M, Kusano M, Sabau SV, Tatsumi H, Imai K, Shinomura Y, Tokino T (2009). A novel method, digital genome scanning detects KRAS gene amplification in gastric cancers: involvement of overexpressed wild-type KRAS in downstream signaling and cancer cell growth. BMC Canc. 9: 198.
   PubMedGoogle Scholar
• Muslin AJ (2008). MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. Clin Sci (Lond). 115: 203–218.
   PubMed Web of Science ®Google Scholar
• Naguib A, Wilson CH, Adams DJ, Arends MJ (2011). Activation of K-RAS by co-mutation of codons 19 and 20 is transforming. J Mol Signal. 6: 2.
   PubMedGoogle Scholar
• Nakao M, Kawauchi S, Uchiyama T, Adachi J, Ito H, Chochi Y, Furuya T, Oga A, Sasaki K (2011). DNA copy number aberrations associated with the clinicopathological features of colorectal cancers: Identification of genomic biomarkers by array-based comparative genomic hybridization. Oncol Rep. 25: 1603–1611.
   PubMed Web of Science ®Google Scholar
• Ohnishi T, Tomita N, Monden T, Ohue M, Yana I, Takami K, Yamamoto H, Yagyu T, Kikkawa N, Shimano T, Monden M (1997). A detailed analysis of the role of K-ras gene mutation in the progression of colorectal adenoma. Br J Canc. 75: 341–347.
   PubMed Web of Science ®Google Scholar
• Orecchia R, Infusini E, Sciutto A, Rapallo A, Di Vinci A, Nigro S, Geido E, Giaretti W (2000). Ki-ras activation in vitro affects G1 and G2M cell-cycle transit times and apoptosis. J Pathol. 190: 423–429.
   PubMed Web of Science ®Google Scholar
• Osterop AP, Medema RH, Bos JL, vd Zon GC, Moller DE, Flier JS, Moller W, Maassen JA (1992). Relation between the insulin receptor number in cells, autophosphorylation and insulin-stimulated Ras.GTP formation. J Biol Chem. 267: 14647–14653.
   PubMed Web of Science ®Google Scholar
• Otori K, Oda Y, Sugiyama K, Hasebe T, Mukai K, Fujii T, Tajiri H, Yoshida S, Fukushima S, Esumi H (1997). High frequency of K-ras mutations in human colorectal hyperplastic polyps. Gut. 40: 660–663.
   PubMed Web of Science ®Google Scholar
• Plowman SJ, Berry RL, Bader SA, Luo F, Arends MJ, Harrison DJ, Hooper ML, Patek CE (2006). K-ras 4A and 4B are co-expressed widely in human tissues, and their ratio is altered in sporadic colorectal cancer. J Exp Clin Cancer Res. 25: 259–267.
   PubMed Web of Science ®Google Scholar
• Poulogiannis G, Ichimura K, Hamoudi RA, Luo F, Leung SY, Yuen ST, Harrison DJ, Wyllie AH, Arends MJ (2010). Prognostic relevance of DNA copy number changes in colorectal cancer. J Pathol. 220: 338–347.
   PubMed Web of Science ®Google Scholar
• Pulciani S, Santos E, Lauver AV, Long LK, Robbins KC, Barbacid M (1982). Oncogenes in human tumor cell lines: molecular cloning of a transforming gene from human bladder carcinoma cells. Proc Natl Acad Sci U S A. 79: 2845–2849.
   PubMed Web of Science ®Google Scholar
• Ravingerova T, Barancik M, Strniskova M (2003). Mitogen-activated protein kinases: a new therapeutic target in cardiac pathology. Mol Cell Biochem. 247: 127–138.
   PubMed Web of Science ®Google Scholar
• Ray S, Atkuri KR, Deb-Basu D, Adler AS, Chang HY, Herzenberg LA, Felsher DW (2006). MYC can induce DNA breaks in vivo and in vitro independent of reactive oxygen species. Canc Res. 66: 6598–6605.
   PubMed Web of Science ®Google Scholar
• Saavedra HI, Knauf JA, Shirokawa JM, Wang J, Ouyang B, Elisei R, Stambrook PJ, Fagin JA (2000). The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway. Oncogene. 19: 3948–3954.
   PubMed Web of Science ®Google Scholar
• Sansom OJ, Meniel V, Wilkins JA, Cole AM, Oien KA, Marsh V, Jamieson TJ, Guerra C, Ashton GH, Barbacid M, Clarke AR (2006). Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo. Proc Natl Acad Sci (USA). 103: 14122–14127.
   PubMed Web of Science ®Google Scholar
• Sasaki AT, Carracedo A, Locasale JW, Anastasiou D, Takeuchi K, Kahoud ER, Haviv S, Asara JM, Pandolfi PP, Cantley LC (2011). Ubiquitination of K-Ras enhances activation and facilitates binding to select downstream effectors. Sci Signal. 4: ra13.
   PubMed Web of Science ®Google Scholar
• Scholl C, Frohling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, Silver SJ, Tamayo P, Wadlow RC, Ramaswamy S, Dohner K, Bullinger L, Sandy P, Boehm JS, Root DE, Jacks T, Hahn WC, Gilliland DG (2009). Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell. 137: 821–834.
   PubMed Web of Science ®Google Scholar
• Segal M, Clarke DJ (2001). The Ras pathway and spindle assembly collide? Bioessays. 23: 307–310.
   PubMed Web of Science ®Google Scholar
• Shih C, Weinberg RA (1982). Isolation of a transforming sequence from a human bladder carcinoma cell line. Cell. 29: 161–169.
   PubMed Web of Science ®Google Scholar
• Shimizu K, Goldfarb M, Perucho M, Wigler M (1983). Isolation and preliminary characterization of the transforming gene of a human neuroblastoma cell line. Proc Natl Acad Sci U S A. 80: 383–387.
   PubMed Web of Science ®Google Scholar
• Shin KH, Bae SD, Hong HS, Kim RH, Kang MK, Park NH (2011). miR-181a shows tumor suppressive effect against oral squamous cell carcinoma cells by downregulating K-ras. Biochem Biophys Res Comm. 404: 896–902.
   PubMed Web of Science ®Google Scholar
• Shivapurkar N, Huang L, Ruggeri B, Swalsky PA, Bakker A, Finkelstein S, Frost A, Silverberg S (1997). K-ras and p53 mutations in aberrant crypt foci and colonic tumors from colon cancer patients. Canc Lett. 115: 39–46.
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Kozuch PS (2011). Impact of KRAS mutations on management of colorectal carcinoma. Patholog Res Int. 2011: xs219–309.
   Google Scholar
• Sweet-Cordero A, Mukherjee S, Subramanian A, You H, Roix JJ, Ladd-Acosta C, Mesirov J, Golub TR, Jacks T (2005). An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet. 37: 48–55.
   PubMed Web of Science ®Google Scholar
• Tanaka H, Matsumura I, Ezoe S, Satoh Y, Sakamaki T, Albanese C, Machii T, Pestell RG, Kanakura Y (2002). E2F1 and c-Myc potentiate apoptosis through inhibition of NF-kappaB activity that facilitates MnSOD-mediated ROS elimination. Mol Cell. 9:1017–1029.
   PubMed Web of Science ®Google Scholar
• Tsang WP, Kwok TT (2009). The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras. Carcinogenesis. 30: 953–959.
   PubMed Web of Science ®Google Scholar
• Vafa O, Wade M, Kern S, Beeche M, Pandita TK, Hampton GM, Wahl GM (2002). c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell. 9: 1031–1044.
   PubMed Web of Science ®Google Scholar
• Vicent S, Chen R, Sayles LC, Lin C, Walker RG, Gillespie AK, Subramanian A, Hinkle G, Yang X, Saif S, Root DE, Huff V, Hahn WC, Sweet-Cordero EA (2010). Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models. J Clin Invest. 120: 3940–3952.
   PubMed Web of Science ®Google Scholar